- authorisedTherapeutic exploratory (Phase II)
Local and systemic immune modulation by Rilvegostomig (AZD2936) in the treatment of advanced gastric cancer (RILVE Project)
This study tests a new medicine called rilvegostomig for adults with advanced stomach cancer who have not yet had treatment. Researchers want to see how well it helps the body's immune system fight tumour cells. They will check its safety and how it affects tumour growth over time.
Spain - active not recruitingPHASE2
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
This study looks at a new combination of experimental drugs, disitamab vedotin and tucatinib, for advanced breast or stomach cancers that have a specific marker called HER2. It aims to see how safe and effective this treatment is, and what side effects it might cause.
United States · Australia · Canada - recruitingPHASE2
Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers
This study aims to understand why some cancer treatments, called ADCs, stop working. By looking at samples from patients with advanced breast, stomach, bladder, or lung cancer, researchers hope to find better ways to choose the right ADC for each person and reduce side effects.
France